Portfolio Companies News
April 24, 2019Oncopeptides provides new guidance ...
Stockholm – 24 April 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study OCEAN, as well as a general update from all the company’s clinical studies in a webcast at 10.00am (CET) today... read more
April 24, 2019GenSight Biologics Reports Full Yea...
Paris, France, April 24, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, toda... read more
April 23, 2019Vicore Pharma announces systemic sc...
Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21), which complements the primary indication, idiopathic pulmonary fibrosis... read more
April 18, 2019BONESUPPORT HOLDING AB (publ) publi...
BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release. About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative inj... read more
April 17, 2019GenSight Biologics reports positive...
GS010-treated eyes showed continuous recovery of visual functions from nadir (worst vision post-treatment) in both best-corrected visual acuity (BCVA) and contrast sensitivity (CS) GS010-treated eyes recovered 21 ETDRS letters from nadir at Week 72 Bilateral improvements in visual function... read more
February 18, 2019Q4 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 113 portfolio companies.
42 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.